Harris RA - Search Results

1

Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.

Parsonnet J, Harris RA, Hack HM, Owens DK. Parsonnet J, et al. Among authors: harris ra. Lancet. 1996 Jul 20;348(9021):150-4. doi: 10.1016/s0140-6736(96)01501-2. Lancet. 1996. PMID: 8684154

2

Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?

Harris RA, Owens DK, Witherell H, Parsonnet J. Harris RA, et al. Helicobacter. 1999 Jun;4(2):69-76. doi: 10.1046/j.1523-5378.1999.98057.x. Helicobacter. 1999. PMID: 10382118

3

The importance of patient preferences for comorbidities in cost-effectiveness analyses.

Harris RA, Nease RF Jr. Harris RA, et al. J Health Econ. 1997 Feb;16(1):113-9. doi: 10.1016/s0167-6296(96)00510-3. J Health Econ. 1997. PMID: 10167342

4

The role of coronary angiography and coronary revascularization before noncardiac vascular surgery.

Mason JJ, Owens DK, Harris RA, Cooke JP, Hlatky MA. Mason JJ, et al. Among authors: harris ra. JAMA. 1995 Jun 28;273(24):1919-25. JAMA. 1995. PMID: 7783301

5

Should we treat H. pylori infection to prevent gastric cancer?

Parsonnet J, Harris RA, Hack HM, Owens DK. Parsonnet J, et al. Among authors: harris ra. Gastroenterology. 1997 Mar;112(3):1044-5. doi: 10.1053/gast.1997.v112.agast971044. Gastroenterology. 1997. PMID: 9041272 No abstract available.

6

Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.

Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Owens DK, et al. Among authors: harris ra. Ann Intern Med. 1997 Jan 1;126(1):1-12. doi: 10.7326/0003-4819-126-1-199701010-00001. Ann Intern Med. 1997. PMID: 8992917

7

Screening surgeons for HIV infection. A cost-effectiveness analysis.

Owens DK, Harris RA, Scott PM, Nease RF Jr. Owens DK, et al. Among authors: harris ra. Ann Intern Med. 1995 May 1;122(9):641-52. doi: 10.7326/0003-4819-122-9-199505010-00001. Ann Intern Med. 1995. PMID: 7702225

8

Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.

Harris RA, Kuppermann M, Richter JE. Harris RA, et al. Am J Gastroenterol. 1997 Dec;92(12):2179-87. Am J Gastroenterol. 1997. PMID: 9399748

9

Economic heartburn: average cost-effectiveness and gastroesophageal reflux disease.

Harris RA, Nease RF. Harris RA, et al. Gastroenterology. 1995 Jan;108(1):303-4. doi: 10.1016/0016-5085(95)90046-2. Gastroenterology. 1995. PMID: 7806058 No abstract available.

10

Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.

Harris RA, Kuppermann M, Richter JE. Harris RA, et al. Am J Med. 1997 Jan;102(1):78-88. doi: 10.1016/s0002-9343(96)00301-4. Am J Med. 1997. PMID: 9209204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results